State Street Corp Ventyx Biosciences, Inc. Transaction History

State Street Corp

$2.21 Trillion
Q1 2024

A detailed history of State Street Corp transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, State Street Corp holds 926,589 shares of VTYX stock, worth $4.43 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

926,589

Previous 990,423 6.45%

Holding current value

$4.43 Million

Previous $2.45 Million 108.34%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.9 - $10.13 $121,284 - $646,638	-63,834 Reduced 6.45%	926,589 $5.1 Million
Q4 2023 Feb 14, 2024	SELL	$2.08 - $31.18 $220,679 - $3.31 Million	-106,096 Reduced 9.68%	990,423 $2.45 Million
Q3 2023 Nov 14, 2023	BUY	$29.8 - $40.3 $1.68 Million - $2.27 Million	56,421 Added 5.42%	1,096,519 $38.1 Million
Q2 2023 Aug 14, 2023	BUY	$28.53 - $39.55 $12.6 Million - $17.4 Million	440,271 Added 73.4%	1,040,098 $34.1 Million
Q1 2023 May 15, 2023	BUY	$29.51 - $46.65 $1.41 Million - $2.23 Million	47,821 Added 8.66%	599,827 $20.1 Million

Q4 2022 Feb 14, 2023	BUY	$24.16 - $36.38 $2.68 Million - $4.04 Million	111,063 Added 25.19%	552,006 $18.1 Million
Q3 2022 Nov 15, 2022	BUY	$12.64 - $38.7 $1.46 Million - $4.47 Million	115,607 Added 35.53%	440,943 $15.4 Million
Q2 2022 Aug 15, 2022	BUY	$11.95 - $18.75 $1.84 Million - $2.89 Million	154,141 Added 90.04%	325,336 $3.98 Million
Q1 2022 May 16, 2022	BUY	$10.0 - $19.98 $675,900 - $1.35 Million	67,590 Added 65.24%	171,195 $2.32 Million
Q4 2021 Feb 14, 2022	BUY	$14.2 - $23.07 $1.47 Million - $2.39 Million	103,605 New	103,605 $2.06 Million

Others Institutions Holding VTYX

# of Institutions

134

Shares Held

59.2M

Call Options Held

180K

Put Options Held

179K

View Full List

About Ventyx Biosciences, Inc.

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $270M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

More about VTYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Ventyx Biosciences, Inc. Transaction History